What the FDA labels say about taking them together
Atazanavir and dabigatran
Atazanavir's FDA label of August 6, 2025 names dabigatran in its drug interactions section; the dabigatran labels PlainMeds reads (2) do not name atazanavir. The atazanavir label: “Concomitant use of REYATAZ with ritonavir, a strong CYP3A4/P-gp inhibitor, may result in an increased risk of bleeding. Refer to the respective DOAC prescribing information regarding dosing instructions for …”
Check it at the source: the atazanavir FDA label on DailyMed (effective August 6, 2025, Aurobindo Pharma Limited); the dabigatran FDA label on DailyMed (effective June 25, 2025, Boehringer Ingelheim Pharmaceuticals Inc.).
What does the atazanavir label say about dabigatran?
Atazanavir label, drug interactionsConcomitant Drug Class/Specific Drugs: Direct-Acting Oral Anticoagulants: betrixaban, dabigatran, edoxaban; Effect on Concentration of Atazanavir or Concomitant Drug: ↑ betrixaban ↑ dabigatran ↑ edoxaban; Clinical Comment: Concomitant use of atazanavir with ritonavir, a strong CYP3A4/P-gp inhibitor, may result in an increased risk of bleeding. Refer to the respective DOAC prescribing information regarding dosing instructions for coadministration with P-gp inhibitors.
Source: FDA drug label (Reyataz, NDA021567), E.R. Squibb & Sons, L.L.C., effective December 5, 2024 (SPL set 165cff62-b284-4a27-a65d-9ec8a5bfcdd8), via openFDA
Source: FDA drug label (Atazanavir Sulfate), Aurobindo Pharma Limited, effective August 6, 2025 (SPL set 7fbea274-d6b5-4faa-bbf0-05fefab42114), via openFDA; the full label on DailyMed
What does the dabigatran label say about atazanavir?
Dabigatran's label (effective June 25, 2025) and its 1 other brand-application label do not name atazanavir in these sections. A label lists what its studies and reports found; it is not a complete list.
Source: FDA drug label (Pradaxa), Boehringer Ingelheim Pharmaceuticals Inc., effective June 25, 2025 (SPL set ba74e3cd-b06f-4145-b284-5fd6b84ff3c9), via openFDA; the full label on DailyMed
These are the labels' own sentences. PlainMeds does not grade interactions; a pharmacist or prescriber can say what they mean for one person's medicines.
Both medicines on the record
| Atazanavir | Dabigatran | |
|---|---|---|
| Labeled for | HIV | Atrial fibrillation, Blood clots (DVT and PE), Stroke prevention |
| Boxed warning | No | Yes |
| Pharmacy cost (NADAC) | $2.23 per capsule 300 mg capsule | $0.795 per capsule 150 mg capsule |
| Shortage now | No current entry | No current entry |
Source: FDA NDC Directory, CMS NADAC of October 7, 2026 and the FDA Drug Shortage Database (FDA files October 8, 2026)
What next?
- Check more medicines together
- up to five at once